Teva Pharmaceutical Industries Ltd banner

Teva Pharmaceutical Industries Ltd
TASE:TEVA

Watchlist Manager
Teva Pharmaceutical Industries Ltd Logo
Teva Pharmaceutical Industries Ltd
TASE:TEVA
Watchlist
Price: 9 199 ILS -4.75% Market Closed
Market Cap: ₪103.6B

TEVA's latest stock split occurred on Jun 27, 2004

The company executed a 2-for-1 stock split, meaning that for every share held, investors received 2 new shares.

The adjusted shares began trading on Jun 27, 2004. This was TEVA's 2nd stock split, following the previous one in Dec 11, 2002.

Last Splits:
Jun 27, 2004
2-for-1
Dec 11, 2002
2-for-1
Pre-Split Price
N/A
Post-Split Price
13 407.3718
Before
After
Last Splits:
Jun 27, 2004
2-for-1
Dec 11, 2002
2-for-1

Teva Pharmaceutical Industries Ltd
Stock Splits History

TEVA Stock Splits Timeline
Jun 27, 2004
Jun 27, 2004
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
13 407.3718
Before
After
Dec 11, 2002
Dec 11, 2002
Split 2-for-1
x2
Pre-Split Price
N/A
Post-Split Price
13 407.3718
Before
After

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
Apr 23, 2026
Red Sky Energy Ltd
ASX:ROG
5-for-4
x1.25
0.002 0.0016 AUD 0.002 0.002 AUD
Apr 23, 2026
J
Jiusheng Electric Co Ltd
SZSE:301082
1-for-1
x1
17.33 13.2508 CNY 12.9 12.9 CNY
Apr 23, 2026
S
Saudee Group Bhd
KLSE:SAUDEE
1-for-10
/10
0.01 0.1 MYR 0.09 0.09 MYR
Apr 23, 2026
Focus Technology Co Ltd
SZSE:002315
1-for-1
x1
44.3999 33.4538 CNY 32 32 CNY
Apr 22, 2026
S
Sharetronic Data Technology Co Ltd
SZSE:300857
1-for-1
x1
304.5701 217.2101 CNY 260.76 260.76 CNY
Load More

Teva Pharmaceutical Industries Ltd
Glance View

Teva Pharmaceutical Industries Ltd., a titan in the global pharmaceutical landscape, has navigated the intricate world of pharmaceuticals with a blend of strategic vision and operational efficiency. Founded in 1901 and headquartered in Israel, Teva has become synonymous with the production of affordable generic medications, a key pillar of its business model. The company's narrative is one of adaptability and foresight, having positioned itself as a leader in the generic drug sector by leveraging economies of scale and a vast distribution network. By acquiring and integrating smaller pharmaceutical firms over the years, Teva has expanded its portfolio to include a vast array of treatments that address a broad spectrum of therapeutic areas. This strategic expansion has enabled the company to offer nearly the same efficacy as brand-name drugs at a fraction of the cost, thus capturing significant market share and delivering value to both patients and healthcare systems worldwide. Beyond its prowess in generics, Teva has carved a niche in the specialty medicines market, focusing on innovative therapies that address complex conditions such as multiple sclerosis, migraine, and movement disorders. This dual-track approach to growth allows Teva to balance the volume-driven nature of the generics market with the higher margins offered by specialty drugs. The synthesis of these two facets – comprehensive generic offerings and targeted specialty pharmaceuticals – underpins Teva's revenue streams. Through a combination of robust pipeline development, strategic partnerships, and a commitment to operational excellence, Teva navigates the challenges of a competitive industry marked by ever-evolving regulations and pricing pressures, striving to maintain its status as a reliable provider of healthcare solutions on a global scale.

TEVA Intrinsic Value
4 992.69 ILS
Overvaluation 46%
Intrinsic Value
Price ₪9 199
Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett